Effectiveness and safety of SARS-CoV-2 vaccine in Inflammatory Bowel Disease patients: a systematic review, meta-analysis and meta-regression.
Journal
Alimentary pharmacology & therapeutics
ISSN: 1365-2036
Titre abrégé: Aliment Pharmacol Ther
Pays: England
ID NLM: 8707234
Informations de publication
Date de publication:
05 2022
05 2022
Historique:
revised:
07
02
2022
received:
10
01
2022
accepted:
18
03
2022
pubmed:
1
4
2022
medline:
29
4
2022
entrez:
31
3
2022
Statut:
ppublish
Résumé
There are concerns regarding the effectiveness and safety of SARS-CoV-2 vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review and meta-analysis comprehensively summarises the available literature regarding the safety and effectiveness of SARS-CoV-2 vaccine in IBD. Three independent reviewers performed a comprehensive review of all original articles describing the response of SARS-CoV-2 vaccines in patients with IBD. Primary outcomes were (1) pooled seroconversion rate SARS-CoV-2 vaccination in IBD patients (2) comparison of breakthrough COVID-19 infection rate SARS-CoV-2 vaccination in IBD patients with control cohort and (3) pooled adverse event rate of SARS-CoV-2 vaccine. All outcomes were evaluated for one and two doses of SARS-CoV-2 vaccine. Meta-regression was performed. Probability of publication bias was assessed using funnel plots and with Egger's test. Twenty-one studies yielded a pooled seroconversion rate of 73.7% and 96.8% in IBD patients after one and two doses of SARS-CoV-2 vaccine respectively. Sub-group analysis revealed non-statistically significant differences between different immunosuppressive regimens for seroconversion. Meta-regression revealed that the vaccine type and study location independently influenced seroconversion rates. There was no statistically significant difference in breakthrough infection in IBD patients as compared to control after vaccination. In summary, the systematic review and meta-analysis suggest that SARS-CoV-2 vaccine is safe and effective in IBD patients.
Identifiants
pubmed: 35355306
doi: 10.1111/apt.16913
pmc: PMC9111455
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1244-1264Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK119544
Pays : United States
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
JAMA. 2021 Jun 1;325(21):2201-2202
pubmed: 33818592
Inflamm Bowel Dis. 2021 Oct 20;27(11):1862-1864
pubmed: 34427638
Gastroenterology. 2021 Sep;161(3):827-836
pubmed: 34048782
Clin Gastroenterol Hepatol. 2022 Jun;20(6):e1263-e1282
pubmed: 34954338
Gastroenterology. 2008 Apr;134(4):929-36
pubmed: 18294633
MMWR Morb Mortal Wkly Rep. 2021 Nov 05;70(44):1545-1552
pubmed: 34735422
Dig Dis. 2021 Dec 10;:
pubmed: 34915480
Gastroenterology. 2021 Nov;161(5):1715-1717.e1
pubmed: 34224740
Gastroenterology. 2022 Feb;162(2):454-467
pubmed: 34717923
Inflamm Bowel Dis. 2021 Nov 29;:
pubmed: 34849919
Am J Gastroenterol. 2022 Jan 1;117(1):176-179
pubmed: 34797219
Gut. 2021 Oct;70(10):1884-1893
pubmed: 33903149
Inflamm Bowel Dis. 2021 Dec 06;:
pubmed: 34871388
Autoimmun Rev. 2022 Jan;21(1):102927
pubmed: 34474172
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
J Clin Med. 2021 Nov 18;10(22):
pubmed: 34830644
Clin Gastroenterol Hepatol. 2020 Nov;18(12):2689-2700
pubmed: 32777550
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):218-224
pubmed: 33508241
Microbiol Spectr. 2021 Dec 22;9(3):e0116221
pubmed: 34756093
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Nature. 2020 Oct;586(7830):567-571
pubmed: 32756549
Gut. 2021 Nov 24;:
pubmed: 34819330
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
J Crohns Colitis. 2022 May 10;16(4):687-688
pubmed: 34718478
Gastroenterology. 2022 Jan;162(1):349-350
pubmed: 34015337
J Crohns Colitis. 2022 Feb 23;16(2):251-258
pubmed: 34379729
Gastroenterology. 2021 Aug;161(2):715-718.e4
pubmed: 33887219
Cell. 2020 Nov 12;183(4):996-1012.e19
pubmed: 33010815
Clin Gastroenterol Hepatol. 2022 Jun;20(6):e1493-e1499
pubmed: 34896283
Gastroenterology. 2021 Dec;161(6):2041-2043.e1
pubmed: 34391771
N Engl J Med. 2022 Jan 13;386(2):105-115
pubmed: 34942066
Aliment Pharmacol Ther. 2022 May;55(10):1244-1264
pubmed: 35355306
Ann Intern Med. 2021 Dec;174(12):1768-1770
pubmed: 34633830
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Cochrane Database Syst Rev. 2019 Oct 3;10:ED000142
pubmed: 31643080
Front Public Health. 2021 Jun 09;9:674597
pubmed: 34178929
Gut. 2021 Apr;70(4):635-640
pubmed: 33472895
Gastroenterology. 2021 Oct;161(4):1336-1339.e3
pubmed: 34144044
Indian J Psychol Med. 2020 Oct 13;42(6):575-576
pubmed: 33354086
Gastroenterology. 2020 Jul;159(1):350-357
pubmed: 32283100
J Crohns Colitis. 2007 Sep;1(1):10-20
pubmed: 21172179
Dis Markers. 2021 Jan 6;2021:8810196
pubmed: 33532006
Nat Rev Gastroenterol Hepatol. 2021 Jan;18(1):56-66
pubmed: 33033392
Gastroenterology. 2021 Oct;161(4):1340-1343.e2
pubmed: 34144046
J Educ Health Promot. 2020 Oct 30;9:289
pubmed: 33282994
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088